price target
downsid risk
encourag solid start year improv full-year outlook still
allow stiffer headwind come quarter maintain posit rate trim
price target
teva beat-and-rais impress turnaround recent histori even ex-
copaxon revenu held better expect enough strength brand
intern off-set continu pressur us gener manag measur
optim increas full-year revenu ebitda guidanc less
beat seem appropri midpoint pull fremanezumab
approv year could posit surpris far assur
